Skip to content
MarketScale
‹ Back to IndustriesHealthcare

NAVIGATING THE AGILE APPROACH TO MEDICAL PRODUCT DEVELOPMENT

Engineers love to build things! Sunrise is working to keep it that way. Traditionally, development of medical products was done using a “waterfall” development process where each phase of a project builds on the previous phase to deliver exactly what was defined in requirements up front. Agile offers a more flexible approach that maintains the…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Engineers love to build things! Sunrise is working to keep it that way.

Traditionally, development of medical products was done using a “waterfall” development process where each phase of a project builds on the previous phase to deliver exactly what was defined in requirements up front. Agile offers a more flexible approach that maintains the needed medical rigor, maximizes learning, and allows requirements to evolve to a more optimum solution.

As identified in AAMI TIR45:2012, the Agile approach to Medical Product development is intended to improve development in 5 basic areas:

  • Quality
  • Productivity
  • Predictability
  • Product effectiveness
  • Safety

Quality is measured during development rather than waiting until the project is complete. The Agile methodology builds the concept of “done” into the process by requiring testing as you go. This in turn, improves on productivity as the engineers who work on the project understand before approaching a task what it means to be “done.” The engineers, on a regular basis, and regardless of the stage of development, demonstrate an operational product to the “owner”.

These frequent demonstrations improve product effectiveness as the “owner” is able to see, touch, and feel the product during the entire process. This also helps to predict when and where the project is with relation to schedule and cost.

Questions concerning product safety, clinician-backed confidence, and consumer opinion are a few of many inquiries that can direct the course of a medical product’s development. Setting strict feature sets without the ability to adjust; strict schedules without the ability to adjust; and rigid budgets without the ability to adjust can be detrimental to the end goal. As a result, Agile product development has become an increasingly popular approach to developing medical products.

The Agile methodology enhances an engineer’s fundamental thought process by:

  • Decomposing large problems into manageable tasks called stories
  • Defining “Done” for each story
  • Providing better visibility for team members, management, and the client about the progress of projects
  • Consistently building products using the same process throughout the company and with all disciplines

Agile product development is customer focused. The process encourages stakeholder and developer collaboration, and bases success on the safety and efficacy efficiency of the final product. A few ways to approach this type of project management style in the development of medical devices are:

Safety and Risk

With the needs of the end user clearly identified, the solution must be designed to solve the problem at hand without undue risk and safety exposure. Risk management activities are part of the development process, and integrating risk management into product development is critical to ensure safety and efficacy. Risk mitigations are converted into requirements, and ultimately into Agile stories and managed like any other feature. These safety requirements are decomposed into manageable tasks and put into stories.

System and Software Architecture 

System and Software development is highly iterative by nature, more so when using the agile development process. Developing robust system and software architectures during the planning phases provides a proper foundation for the subsequent design phases.

Team Synergy

Collaboration among team members is essential to ensuring that product development stays on track. Knowledge barriers can be avoided when team members are aware of the bigger picture and understand where the project is and where the project is going. Agile development encourages collaboration to break down roadblocks and spur productivity. Using Agile development across the organization helps engineers and managers to coordinate activities across disciplines including electrical and mechanical engineering.

Feedback Loop

As mentioned above, demonstrations of prototypes to stakeholders in the early phases can yield valuable feedback to improve and refine the final product before costly V&V activities commence. Required usability studies for medical products by the FDA and ISO are other more formal opportunities to gather feedback. The Agile process requires the product is operational after each step in the process, ensuring working prototypes for testing.

Sunrise Solution

Developing medical products is fun. Our goal at Sunrise is to keep it that way and make it more a more predictable process that meets the customer’s needs. The Agile methodology is a powerful tool that can be utilized in the medical product development process to allow flexibility and aid in creating improved products.

Sunrise Labs has the expertise to take innovative ideas from concept to reality. The commercial medical device industry is complex and in constant flux, therefore clients leverage our expertise to overcome design challenges while satisfying regulatory requirements. At Sunrise, our passion is improving patient outcomes by helping our clients succeed in the development of beneficial medical devices.

Learn more about Sunrise Labs, our team, services, and values today.

Read more at sunriselabs.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512